Clearside Biomedical (NASDAQ:CLSD – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.
CLSD has been the subject of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.75.
View Our Latest Stock Report on Clearside Biomedical
Clearside Biomedical Stock Up 9.0 %
Institutional Investors Weigh In On Clearside Biomedical
A number of institutional investors have recently added to or reduced their stakes in CLSD. Johnson & Johnson purchased a new stake in Clearside Biomedical during the third quarter valued at about $105,000. Geode Capital Management LLC grew its position in Clearside Biomedical by 8.8% during the third quarter. Geode Capital Management LLC now owns 731,386 shares of the company’s stock valued at $929,000 after acquiring an additional 59,089 shares during the period. Investor s Fiduciary Advisor Network LLC purchased a new stake in Clearside Biomedical during the fourth quarter valued at about $32,000. Finally, Northern Trust Corp grew its position in Clearside Biomedical by 24.0% during the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock valued at $157,000 after acquiring an additional 32,048 shares during the period. Hedge funds and other institutional investors own 18.75% of the company’s stock.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Featured Stories
- Five stocks we like better than Clearside Biomedical
- How to Invest in the Best Canadian Stocks
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Conference Calls and Individual Investors
- 3 Must-Own Stocks to Build Wealth This Decade
- 3 REITs to Buy and Hold for the Long Term
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.